Alessandro Di Federico
机构：Dana-Farber Cancer Institute, Azienda USL di Bologna, University of Bologna
发表论文 6 篇
代表论文
- PP01.43: Machine Learning-Guided Treatment Selection for KRAS-Altered and Wild-Type Metastatic Non-Squamous Non-Small Cell Lung Cancer (2026 · Journal of Thoracic Oncology)
- PP01.07: Activity of Bevacizumab Combined With Chemotherapy in Advanced RET-Rearranged Non-Small Cell Lung Cancer (2026 · Journal of Thoracic Oncology)
- PP01.47: PD-(L)1 Inhibitor Monotherapy Versus Chemo-Immunotherapy for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and PD-L1 Expression ≥50%: A Systematic Review and Meta-Analysis with Individual Patient Data (2026 · Journal of Thoracic Oncology)
- PP01.20: Integrating Clinicopathologic and Genomic Features to Identify Patients at Risk of Earlier Progression to First-Line Osimertinib in EGFR-Mutant NSCLC (2026 · Journal of Thoracic Oncology)
- OA01.04: Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors (2026 · Journal of Thoracic Oncology)
- PP01.01: Genomic Determinants of Acquired Resistance to BRAF/MEK Inhibitors in BRAF V600E-Mutant Non-Small Cell Lung Cancer (2026 · Journal of Thoracic Oncology)